Lytix Biopharma ASA LYTIX
Oslo Børs · Healthcare · Biotechnology
7.90 NOK
−1.2%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Lytix Biopharma
| NOK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 11 | 4 | 11 | 0 |
| EBITDA | −55 | −87 | −93 | −59 |
| Net income | −56 | −88 | −94 | −60 |
| Balance sheet | ||||
| Equity | 135 | 51 | 108 | 62 |
| Total debt | 1 | 0 | 3 | 2 |
| Cash | 93 | 26 | 129 | 10 |
| Net debt | −92 | −25 | −127 | −8 |
| Ratios and per share | ||||
| EBITDA margin | −498.6% | −2,176.9% | −837.4% | – |
| Profit margin | −508.3% | −2,202.4% | −846.7% | – |
| Return on equity | −41.5% | −171.3% | −87.4% | −97.1% |
| Earnings/share (NOK) | −1.39 | −2.18 | −1.38 | −0.87 |
| Book value/share (NOK) | 3.35 | 1.27 | 1.58 | 0.90 |
| Shares outstanding (M) | 40 | 40 | 68 | 69 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | – |
| P/B | 8.8 |
| EV / EBITDA | – |
| Net debt / EBITDA | – |
| Return on equity | −97.1% |
| Profit margin | – |
| Beta 1Y | 0.41 |
| Revenue growth 1Y | −100.0% |
| ROE avg. 3Y | −118.6% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (NOK)
No dividends paid in the last five years.
Not investment advice. Figures may contain errors from the data source.